Stanford Radiology has entered a collaboration with Atley Solutions and Telix Pharmaceuticals to develop a California-based operational supply chain for astatine‑211 (At‑211), an alpha‑emitting radionuclide used in targeted radionuclide therapy and theranostics.
The initiative is intended to expand research access to the isotope and support future clinical translation at Stanford and across the western U.S., Stanford said.
Under the agreement, an Atley C100 module will be installed at Stanford, enabling validation of the complete astatine-211 (At‑211) radiopharmaceutical workflow, from target processing through manufacture of the final drug product, according to Stanford. Telix will support radiopharmaceutical clinical development and commercialization.
Production will take place at the Crocker Nuclear Laboratory at University of California, Davis, Stanford noted, adding that its cyclotron and radiochemistry facility (CRF) will oversee purification, radiochemistry, and validation activities. The CRF expects to produce its first At‑211‑labeled investigational compound later this year.
At‑211 has shown promise for treating metastatic disease, but limited regional availability has slowed translational research, according to Stanford. The effort strengthens its infrastructure for advancing novel radiopharmaceuticals from early research to clinical evaluation.
The project runs through 2026 and is funded by VINNOVA through a 2025 collaboration with the U.S., U.K., and Singapore.
